Form 4: IO Biotech CFO Acquires Stock Options

Amy Sullivan, CFO of IO Biotech, Inc., reports the acquisition of stock options.

Summary

• Amy Sullivan, the Chief Financial Officer of IO Biotech, Inc. (IOBT), filed a Form 4 on April 4, 2025, reporting a transaction.
• On April 2, 2025, Sullivan acquired stock options for 215,000 shares of common stock at an exercise price of $1.07.
• The options vest over time, with one-fourth vesting on April 2, 2026, and the remainder vesting monthly thereafter, contingent on continued service.
• The vesting schedule includes acceleration clauses upon certain termination events.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally neutral to positive as it incentivizes management. There are no red flags or negative implications.

Positives

• The acquisition of stock options by the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

This type of stock option grant is a common practice in the biotech industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to align executive incentives with shareholder value.
• The vesting schedule and acceleration clauses are also typical features designed to retain talent and protect against adverse events like termination or change of control.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates

Keywords

IO Biotech, IOBT, Form 4, Stock Options, Amy Sullivan, CFO, Beneficial Ownership, Securities